<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081960</url>
  </required_header>
  <id_info>
    <org_study_id>119537</org_study_id>
    <nct_id>NCT05081960</nct_id>
  </id_info>
  <brief_title>Evaluating the Vitamin K2 Status of Calcium-based Stone Formers</brief_title>
  <official_title>Evaluating the Vitamin K2 Status of Calcium-based Stone Formers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Health Care London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observation, single site-study with one study visit during which all data and&#xD;
      samples will be collected. Study participants will be asked to provide blood, urine, and&#xD;
      fecal samples so that the investigators may study the differences in the gut microbiota,&#xD;
      vitamin K2 levels, and other parameters between participants who form kidney stones and those&#xD;
      who do not.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that calcium-based stone formers will have an altered fecal gut microbiota&#xD;
      compared to non-stone former controls. This altered microbiota will have a lower abundance of&#xD;
      bacteria that produce menaquinones (vitamin K2), thus stone formers will also have a&#xD;
      different blood menaquinone profile compared to controls. Ultimately, the different levels of&#xD;
      menaquinones will result in increased inactive Matrix Gla protein (dp-ucMGP), which is a key&#xD;
      protein that sequesters free calcium. To test this hypothesis, calcium-based stone former and&#xD;
      non-stone forming controls will be recruited to a single site, observation study to collect&#xD;
      urine, blood, and fecal samples. These samples will be used to determine dp-ucMGP levels,&#xD;
      menaquinone profiles, the composition of the gut microbiota, and other parameters of&#xD;
      interest.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal microbiota composition of stone-formers and controls</measure>
    <time_frame>At baseline only</time_frame>
    <description>Fecal samples will be collected using out validated toilet paper method. Microbial DNA will be extracted and sequenced using next-generation sequencing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of urine dp-ucMGP (dephosphorylated-uncarboxylated Matrix Gla Protein)</measure>
    <time_frame>At baseline only</time_frame>
    <description>dp-ucMGP will be quantified using an enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood dp-ucMGP (dephosphorylated-uncarboxylated Matrix Gla Protein)</measure>
    <time_frame>At baseline only</time_frame>
    <description>dp-ucMGP will be quantified using an enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood total osteocalcin (OC)</measure>
    <time_frame>At baseline only</time_frame>
    <description>Total OC will be quantified using an enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood undercarboxylated osteocalcin (ucOC)</measure>
    <time_frame>At baseline only</time_frame>
    <description>ucOC will be quantified using an enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of urine total osteocalcin (OC)</measure>
    <time_frame>At baseline only</time_frame>
    <description>Total OC will be quantified using an enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of urine undercarboxylated osteocalcin (ucOC)</measure>
    <time_frame>At baseline only</time_frame>
    <description>ucOC will be quantified using an enzyme-linked immunosorbent assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood menaquinones (vitamin K2) - MK-4</measure>
    <time_frame>At baseline only</time_frame>
    <description>Menaquinones will be quantified using liquid chromatography with mass spectrometry or fluorescence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood menaquinones (vitamin K2) - MK-7</measure>
    <time_frame>At baseline only</time_frame>
    <description>Menaquinones will be quantified using liquid chromatography with mass spectrometry or fluorescence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood menaquinones (vitamin K2) - MK-8</measure>
    <time_frame>At baseline only</time_frame>
    <description>Menaquinones will be quantified using liquid chromatography with mass spectrometry or fluorescence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood menaquinones (vitamin K2) - MK-9</measure>
    <time_frame>At baseline only</time_frame>
    <description>Menaquinones will be quantified using liquid chromatography with mass spectrometry or fluorescence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood menaquinones (vitamin K2) - MK-10</measure>
    <time_frame>At baseline only</time_frame>
    <description>Menaquinones will be quantified using liquid chromatography with mass spectrometry or fluorescence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood menaquinones (vitamin K2) - MK-11</measure>
    <time_frame>At baseline only</time_frame>
    <description>Menaquinones will be quantified using liquid chromatography with mass spectrometry or fluorescence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood menaquinones (vitamin K2) - MK-12</measure>
    <time_frame>At baseline only</time_frame>
    <description>Menaquinones will be quantified using liquid chromatography with mass spectrometry or fluorescence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of blood menaquinones (vitamin K2) - MK-13</measure>
    <time_frame>At baseline only</time_frame>
    <description>Menaquinones will be quantified using liquid chromatography with mass spectrometry or fluorescence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of blood fetuin A</measure>
    <time_frame>At baseline only</time_frame>
    <description>Fetuin A will be quantified using enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of urine fetuin A</measure>
    <time_frame>At baseline only</time_frame>
    <description>Fetuin A will be quantified using enzyme-linked immunosorbent assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of blood Hemoglobin A1C (HbA1c)</measure>
    <time_frame>At baseline only</time_frame>
    <description>HbA1c will be quantified in the core laboratory as per established protocols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma calcium</measure>
    <time_frame>At baseline only</time_frame>
    <description>Calcium levels will be quantified in the core laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of ionized calcium in blood</measure>
    <time_frame>At baseline only</time_frame>
    <description>Calcium levels will be quantified in the core laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of blood albumin</measure>
    <time_frame>At baseline only</time_frame>
    <description>Albumin levels will be quantified in the core laboratory as per established protocols</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of urinary γ-carboxyglutamic acid</measure>
    <time_frame>At baseline only</time_frame>
    <description>γ-carboxyglutamic acid will be quantified using high-performance liquid chromatography and normalized to creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of urinary creatinine</measure>
    <time_frame>At baseline only</time_frame>
    <description>Creatinine will be quantified using high-performance liquid chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of urinary oxalate</measure>
    <time_frame>At baseline only</time_frame>
    <description>Oxalate will be quantified using high-performance liquid chromatography and normalized to creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of urinary phosphate</measure>
    <time_frame>At baseline only</time_frame>
    <description>Phosphate will be quantified in the core laboratory as per established protocols</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Calculi</condition>
  <condition>Calcium Oxalate Kidney Stones</condition>
  <condition>Vitamin K 2</condition>
  <condition>Human</condition>
  <condition>Kidney Stone</condition>
  <condition>Calcium Oxalate Urolithiasis</condition>
  <condition>Calcium Phosphate Urolithiasis</condition>
  <condition>Nephrolithiasis</condition>
  <arm_group>
    <arm_group_label>Stone Formers</arm_group_label>
    <description>Individuals who have experienced at least one incidence of calcium-based kidney stones in the last 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Individuals who have never had a kidney stone in their lifetime.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, fecal, and blood samples will be collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stone formers will be recruited from the Urology clinic or London and surrounding&#xD;
        community. Controls will be recruited from the London and surrounding community.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male/Female, 18 - 65 years old&#xD;
&#xD;
          -  No self-reported kidney stones during their lifetime (controls)&#xD;
&#xD;
          -  Ultrasound examination confirming absence of kidney stones (controls)&#xD;
&#xD;
          -  Have had at least 1 incidence of a clinically confirmed calcium-based kidney stone in&#xD;
             the last 12 months (stone formers)&#xD;
&#xD;
          -  Ability to collect a clean catch urine sample&#xD;
&#xD;
          -  Prescription and over-the-counter drugs unchanged for ≥30 days&#xD;
&#xD;
          -  Willingness to provide medical information, blood, urine, and fecal samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current, or within 30 days, use of antibiotics or antifungals&#xD;
&#xD;
          -  Current, or within 30 days, use of vitamin K antagonists&#xD;
&#xD;
          -  Current probiotic use or any use within 14 days of screening sample collection should&#xD;
             be recorded&#xD;
&#xD;
          -  A history or currently undergoing immunosuppressive drug therapy, chemotherapy, or&#xD;
             radiation therapy 2021-06-29 1.0 Page 4 of 6&#xD;
&#xD;
          -  Fecal incontinence&#xD;
&#xD;
          -  History of disorder with abnormal calcium regulation such as hyperparathyroidism,&#xD;
             active malignancy, or osteoporosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Bjazevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Heath Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Bjazevic, MD</last_name>
    <phone>519-646-6100</phone>
    <phone_ext>66036</phone_ext>
    <email>Jennifer.Bjazevic@sjhc.london.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John A Chmiel, MSc</last_name>
    <phone>905-912-2382</phone>
    <email>jchmiel4@uwo.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>Fraser JD, Price PA. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J Biol Chem. 1988 Aug 15;263(23):11033-6.</citation>
    <PMID>3042764</PMID>
  </reference>
  <reference>
    <citation>Moe OW. Kidney stones: pathophysiology and medical management. Lancet. 2006 Jan 28;367(9507):333-44. Review.</citation>
    <PMID>16443041</PMID>
  </reference>
  <reference>
    <citation>Stanford J, Charlton K, Stefoska-Needham A, Ibrahim R, Lambert K. The gut microbiota profile of adults with kidney disease and kidney stones: a systematic review of the literature. BMC Nephrol. 2020 Jun 5;21(1):215. doi: 10.1186/s12882-020-01805-w.</citation>
    <PMID>32503496</PMID>
  </reference>
  <results_reference>
    <citation>Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med. 1994 Dec;17(6):531-9.</citation>
    <PMID>7895417</PMID>
  </results_reference>
  <results_reference>
    <citation>Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012 Nov 12;11:93. doi: 10.1186/1475-2891-11-93.</citation>
    <PMID>23140417</PMID>
  </results_reference>
  <results_reference>
    <citation>Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012 Jul;62(1):160-5. doi: 10.1016/j.eururo.2012.03.052. Epub 2012 Mar 31.</citation>
    <PMID>22498635</PMID>
  </results_reference>
  <results_reference>
    <citation>Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis. 2000 Nov-Dec;30(6):298-307.</citation>
    <PMID>11356998</PMID>
  </results_reference>
  <results_reference>
    <citation>Schurgers LJ, Vermeer C. Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochim Biophys Acta. 2002 Feb 15;1570(1):27-32.</citation>
    <PMID>11960685</PMID>
  </results_reference>
  <results_reference>
    <citation>Wei FF, Thijs L, Zhang ZY, Jacobs L, Yang WY, Salvi E, Citterio L, Cauwenberghs N, Kuznetsova T, E A Drummen N, Hara A, Manunta P, Li Y, Verhamme P, Allegaert K, Cusi D, Vermeer C, Staessen JA. The risk of nephrolithiasis is causally related to inactive matrix Gla protein, a marker of vitamin K status: a Mendelian randomization study in a Flemish population. Nephrol Dial Transplant. 2018 Mar 1;33(3):514-522. doi: 10.1093/ndt/gfx014.</citation>
    <PMID>28340119</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Jennifer Bjazevic</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <keyword>Kidney stone disease</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Menaquinone</keyword>
  <keyword>Vitamin K2</keyword>
  <keyword>Matrix Gla protein</keyword>
  <keyword>dp-ucMGP</keyword>
  <keyword>Nephrolithiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

